Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Core Insights - Nxera Pharma's partner, Neurocrine Biosciences, has initiated the Phase 3 registrational program for NBI-1117568 as a potential treatment for schizophrenia, resulting in a $15 million payment to Nxera, which will be recognized as revenue in Q2 2025 [1][2] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [3] - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines in a growing market [3] Pipeline and Research - Nxera is advancing a pipeline of over 30 active programs, utilizing its NxWave™ discovery platform, targeting major unmet needs in neurology/neuropsychiatry, metabolic diseases, and immunology [4] - The Phase 3 study for NBI-1117568 will enroll approximately 280 patients and aims to evaluate the drug's efficacy through the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression of Severity (CGI-S) scale [2]